Beisol Pharma Merkplas: what changed
Position among the sector peers
Sector benchmark: create a free account or sign in to use this tool.
You see every sector peer as a dot per ratio, with the company in two financial years and every ratio over five years against the sector.
What moved between 2025 and 2026
Largest movements
- Receivables within one year -€16,917
down €16,917 (-26.3%), from €64,260 to €47,343
of which Trade receivables: -€18,360
- Other debts -€31,615
down €31,615 (-9.3%), from €338,434 to €306,819
- Profit (loss) carried forward +€21,459
up €21,459 (+22.5%), from -€95,277 to -€73,818
- Trade debts -€5,250
no longer reported in 2026 (was €5,250)
- Gross operating margin -€4,380
down €4,380 (-16.6%), from €26,313 to €21,933
- Purchases and services +€4,380
up €4,380 (+42.1%), from €10,407 to €14,787
Change in the result, 2025 to 2026
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2025 and 2026 balance sheets and the 2026 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2025 | 2026 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €273,077 | €255,874 | -€17,203 | -6.3% |
| Current assets | 29/58 | €273,077 | €255,874 | -€17,203 | -6.3% |
| Stocks and contracts in progress | 3 | €208,524 | €208,524 | = | 0.0% |
| Stocks | 30/36 | €208,524 | €208,524 | = | 0.0% |
| Amounts receivable within one year | 40/41 | €64,260 | €47,343 | -€16,917 | -26.3% |
| Trade receivables | 40 | €64,260 | €45,900 | -€18,360 | -28.6% |
| Other amounts receivable | 41 | - | €1,443 | +€1,443 | |
| Cash at bank and in hand | 54/58 | €293 | €7 | -€286 | -97.6% |
| Total equity and liabilities | 10/49 | €273,077 | €255,874 | -€17,203 | -6.3% |
| Equity | 10/15 | -€72,404 | -€50,945 | +€21,459 | +29.6% |
| Contributions | 10/11 | €6,200 | €6,200 | = | 0.0% |
| Capital | 10 | €6,200 | €6,200 | = | 0.0% |
| Issued capital | 100 | €18,600 | €18,600 | = | 0.0% |
| Uncalled capital | 101 | €12,400 | €12,400 | = | 0.0% |
| Reserves | 13 | €16,673 | €16,673 | = | 0.0% |
| Non-distributable reserves | 130/1 | €834 | €834 | = | 0.0% |
| Legal reserve | 130 | €834 | €834 | = | 0.0% |
| Distributable reserves | 133 | €15,839 | €15,839 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€95,277 | -€73,818 | +€21,459 | +22.5% |
| Amounts payable | 17/49 | €345,481 | €306,819 | -€38,662 | -11.2% |
| Amounts payable within one year | 42/48 | €345,481 | €306,819 | -€38,662 | -11.2% |
| Trade debts | 44 | €5,250 | - | -€5,250 | |
| Suppliers | 440/4 | €5,250 | - | -€5,250 | |
| Taxes, remuneration and social security | 45 | €1,797 | - | -€1,797 | |
| Taxes | 450/3 | €1,797 | - | -€1,797 | |
| Other amounts payable | 47/48 | €338,434 | €306,819 | -€31,615 | -9.3% |
| Turnover | 70 | €36,720 | €36,720 | = | 0.0% |
| Goods, raw materials, services and sundry goods | 60/61 | €10,407 | €14,787 | +€4,380 | +42.1% |
| Other operating charges | 640/8 | €387 | €411 | +€24 | +6.2% |
| Gross operating margin | 9900 | €26,313 | €21,933 | -€4,380 | -16.6% |
| Operating profit (loss) | 9901 | €25,926 | €21,522 | -€4,404 | -17.0% |
| Financial charges | 65/66B | €30 | €63 | +€33 | +110% |
| Recurring financial charges | 65 | €30 | €63 | +€33 | +110% |
| Profit (loss) for the period before taxes | 9903 | €25,896 | €21,459 | -€4,437 | -17.1% |
| Profit (loss) for the period | 9904 | €25,896 | €21,459 | -€4,437 | -17.1% |
| Profit (loss) for the period to be appropriated | 9905 | €25,896 | €21,459 | -€4,437 | -17.1% |
Value
latest balance sheet 31-03-2026 · indication, not a valuation or adviceIndicative value of the equity
Indication, not a valuation or adviceMidpoint €6,740 · 50% capitalised earnings, 50% adjusted equity
Capitalisation rate 12% result over 3 years, excluding non-recurring income and charges earnings weight 50% revaluation €0 other adjustment €0 EBITDA multiple
The filed figures and these assumptions give no positive value. The adjusted equity and the average result are both zero or negative.
Part of the calculation comes out below zero. A shareholding is never worth less than zero, so the floor is zero.
Adjusted equity
- Equity (10/15)
- -€50,945
- Formation expenses (20)
- €0
- Intangible fixed assets (21)
- €0
- Revaluation of assets
- €0
- Deferred tax on the revaluation
- €0
- Other adjustment
- €0
- Adjusted equity
- -€50,945
Capitalised earnings
- 2026
- €21,459
- 2025
- €25,896
- 2024
- -€24,162
- 2023
- -€26,546
- 2022
- -€35,841
- Average result, excluding non-recurring income and charges
- €7,731
- Divided by the capitalisation rate
- 14% / 12% / 10%
- Capitalised earnings
- €55,221 / €64,425 / €77,310
Your EBITDA multiple
- EBITDA 2026
- -
- Net financial debt
- -€7
- Your multiple
- -
- Value with your multiple
- -
These accounts do not break down the debts after one year. They count in full as financial debt.
Limits of the indication
- Checked holds no market prices or comparable transactions.
- Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
- Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
- The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.
For a valuation to base a decision on, go to a company auditor or a certified accountant.
Next steps
Calculation and sources
Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 March 2025 and 31 March 2026. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 9 November 2026 via checked.be.